MRVI

Maravai LifeSciences Holdings, Inc. NASDAQ

Healthcare ·Biotechnology ·US · maravai.com

$3.73

Mkt Cap $541.1M

52w Low $1.95 82.6% of range 52w High $4.11

50d MA $3.27 200d MA $3.14

P/E (TTM) -4.1x

EV/EBITDA -4.9x

P/B 1.4x

Debt/Equity 0.2x

ROE -61.6%

P/FCF -6.7x

RSI (14) —

ATR (14) —

Beta 0.43

50d MA $3.27

200d MA $3.14

Avg Volume 1.6M

About

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based …

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 25, 2026	AMC	-0.07	-0.04	+42.9%	3.26	+9.8%	+9.2%	+9.2%	+10.7%	+13.2%	+17.2%	-12.3%	—
Nov 6, 2025	AMC	-0.06	-0.08	-33.3%	2.89	-11.8%	-0.7%	+7.3%	+12.5%	+12.5%	+12.5%	+24.9%	—
Aug 11, 2025	AMC	-0.06	-0.08	-33.3%	2.06	+13.1%	+30.6%	+33.5%	+26.2%	+26.7%	+24.8%	+26.2%	—
May 12, 2025	AMC	-0.07	-0.08	-14.3%	2.12	+0.0%	-2.8%	-6.6%	-7.5%	-0.9%	+2.4%	+7.5%	—
Mar 18, 2025	AMC	-0.03	-0.06	-100.0%	2.58	-0.8%	-5.8%	-7.0%	-12.0%	-13.2%	-10.9%	-31.4%	—
Nov 7, 2024	AMC	-0.01	-0.02	-150.0%	7.84	-39.4%	-35.2%	-26.3%	-27.3%	-28.2%	-33.7%	-30.7%	—
Aug 7, 2024	AMC	-0.04	-0.08	-100.0%	9.10	-5.4%	-6.8%	-6.2%	-4.4%	-7.3%	-9.7%	-0.5%	—
May 8, 2024	AMC	-0.02	-0.02	-21.3%	8.87	+3.2%	+11.2%	+17.9%	+18.7%	+20.6%	+26.3%	-2.9%	—
Feb 22, 2024	AMC	0.00	0.01	+185.2%	5.11	+36.0%	+63.6%	+57.1%	+61.6%	+56.9%	+51.3%	+66.1%	—
Nov 7, 2023	AMC	-0.00	-0.01	-257.1%	6.88	-11.0%	-31.7%	-31.7%	-25.4%	-28.1%	-24.9%	-24.7%	—
Aug 7, 2023	AMC	-0.03	-0.06	-100.0%	11.02	-14.2%	+0.7%	-2.5%	-6.5%	-6.2%	-8.8%	-1.5%	—
May 8, 2023	AMC	0.04	0.03	-17.1%	13.90	-10.9%	-13.0%	-12.8%	-1.5%	+6.7%	+7.9%	+0.6%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Dec 15	Wells Fargo	Maintains	Overweight → Overweight	—	$3.60	$3.64	+1.1%	+1.9%	-0.3%	-3.9%	-2.2%	-4.7%
Aug 12	RBC Capital	Maintains	Outperform → Outperform	—	$2.06	$2.33	+13.1%	+30.6%	+33.5%	+26.2%	+26.7%	+24.8%
Aug 12	Craig-Hallum	Maintains	Buy → Buy	—	$2.06	$2.33	+13.1%	+30.6%	+33.5%	+26.2%	+26.7%	+24.8%
May 13	Baird	Maintains	Neutral → Neutral	—	$2.12	$2.12	+0.0%	-2.8%	-6.6%	-7.5%	-0.9%	+2.4%
May 13	Craig-Hallum	Maintains	Buy → Buy	—	$2.12	$2.12	+0.0%	-2.8%	-6.6%	-7.5%	-0.9%	+2.4%
Mar 25	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$2.24	$2.25	+0.4%	+2.7%	+5.8%	+4.9%	+5.4%	-1.3%
Mar 21	UBS	Maintains	Neutral → Neutral	—	$2.40	$2.12	-11.7%	-5.4%	-6.7%	-4.2%	-1.2%	-2.1%
Mar 3	BofA Securities	Maintains	Buy → Buy	—	$3.22	$3.20	-0.6%	-6.2%	-11.8%	-12.7%	-17.1%	-8.1%
Feb 26	Baird	Downgrade	Outperform → Neutral	—	$3.14	$3.06	-2.5%	+3.5%	-2.9%	+2.5%	-3.8%	-9.6%
Dec 5	Goldman Sachs	Downgrade	Neutral → Sell	—	$5.42	$5.18	-4.4%	-6.1%	-6.8%	+0.2%	+9.4%	+6.5%
Nov 8	William Blair	Downgrade	Outperform → Market Perform	—	$7.84	$4.75	-39.4%	-35.2%	-26.3%	-27.3%	-28.2%	-33.7%
Nov 8	RBC Capital	Maintains	Outperform → Outperform	—	$7.84	$4.75	-39.4%	-35.2%	-26.3%	-27.3%	-28.2%	-33.7%
Nov 8	Baird	Maintains	Outperform → Outperform	—	$7.84	$4.75	-39.4%	-35.2%	-26.3%	-27.3%	-28.2%	-33.7%
Oct 8	Goldman Sachs	Maintains	Neutral → Neutral	—	$7.83	$7.74	-1.1%	-1.9%	-1.8%	-2.6%	+2.3%	+5.5%
Aug 16	RBC Capital	Maintains	Outperform → Outperform	—	$7.97	$7.98	+0.1%	+21.5%	+15.9%	+12.8%	+10.2%	+11.2%
Aug 13	Morgan Stanley	Downgrade	Overweight → Equal Weight	—	$8.70	$8.30	-4.6%	-3.0%	-5.5%	-8.4%	+11.3%	+6.2%
Aug 8	UBS	Maintains	Neutral → Neutral	—	$9.10	$8.61	-5.4%	-6.8%	-6.2%	-4.4%	-7.3%	-9.7%
Aug 8	Goldman Sachs	Maintains	Neutral → Neutral	—	$9.10	$8.61	-5.4%	-6.8%	-6.2%	-4.4%	-7.3%	-9.7%
Jul 9	Goldman Sachs	Maintains	Neutral → Neutral	—	$7.35	$7.35	+0.0%	+3.0%	+5.0%	+17.0%	+21.6%	+19.2%
May 9	Baird	Maintains	Outperform → Outperform	—	$8.87	$9.15	+3.2%	+11.2%	+17.9%	+18.7%	+20.6%	+26.3%
Feb 23	Stifel	Maintains	Buy → Buy	—	$5.11	$6.95	+36.0%	+63.6%	+57.1%	+61.6%	+56.9%	+51.3%
Feb 23	RBC Capital	Maintains	Outperform → Outperform	—	$5.11	$6.95	+36.0%	+63.6%	+57.1%	+61.6%	+56.9%	+51.3%
Dec 12	BofA Securities	Upgrade	Neutral → Buy	—	$5.15	$5.41	+5.0%	+8.5%	+15.1%	+21.2%	+21.0%	+21.0%
Nov 9	Morgan Stanley	Maintains	Overweight → Overweight	—	$4.70	$4.76	+1.3%	+0.0%	+9.1%	+5.3%	+10.0%	+10.4%
Nov 9	Goldman Sachs	Maintains	Neutral → Neutral	—	$4.70	$4.76	+1.3%	+0.0%	+9.1%	+5.3%	+10.0%	+10.4%
Aug 9	Morgan Stanley	Maintains	Overweight → Overweight	—	$11.10	$11.12	+0.2%	-3.2%	-7.2%	-6.8%	-9.5%	-6.5%
Aug 8	KeyBanc Capital Markets	Downgrade	Overweight → Sector Weight	—	$11.02	$9.45	-14.2%	+0.7%	-2.5%	-6.5%	-6.2%	-8.8%
Aug 8	Baird	Maintains	Outperform → Outperform	—	$11.02	$9.45	-14.2%	+0.7%	-2.5%	-6.5%	-6.2%	-8.8%
Aug 8	RBC Capital	Maintains	Outperform → Outperform	—	$11.02	$9.45	-14.2%	+0.7%	-2.5%	-6.5%	-6.2%	-8.8%
Aug 8	Goldman Sachs	Maintains	Neutral → Neutral	—	$11.02	$9.45	-14.2%	+0.7%	-2.5%	-6.5%	-6.2%	-8.8%
Aug 8	Credit Suisse	Maintains	Neutral → Neutral	—	$11.02	$9.45	-14.2%	+0.7%	-2.5%	-6.5%	-6.2%	-8.8%
Aug 8	Deutsche Bank	Maintains	Buy → Buy	—	$11.02	$9.45	-14.2%	+0.7%	-2.5%	-6.5%	-6.2%	-8.8%
May 23	Credit Suisse	Downgrade	Outperform → Neutral	—	$13.60	$12.88	-5.3%	+0.3%	-1.5%	-2.8%	-4.0%	-4.3%
May 10	Goldman Sachs	Maintains	Neutral → Neutral	—	$12.09	$12.37	+2.3%	+0.2%	+13.2%	+22.7%	+24.1%	+10.8%
May 10	Morgan Stanley	Maintains	Overweight → Overweight	—	$12.09	$12.37	+2.3%	+0.2%	+13.2%	+22.7%	+24.1%	+10.8%
May 9	Goldman Sachs	Downgrade	Buy → Neutral	—	$13.90	$12.39	-10.9%	-13.0%	-12.8%	-1.5%	+6.7%	+7.9%
May 9	Credit Suisse	Maintains	Outperform → Outperform	—	$13.90	$12.39	-10.9%	-13.0%	-12.8%	-1.5%	+6.7%	+7.9%
May 9	RBC Capital	Maintains	Outperform → Outperform	—	$13.90	$12.39	-10.9%	-13.0%	-12.8%	-1.5%	+6.7%	+7.9%
May 9	Deutsche Bank	Maintains	Buy → Buy	—	$13.90	$12.39	-10.9%	-13.0%	-12.8%	-1.5%	+6.7%	+7.9%
Feb 24	Morgan Stanley	Maintains	Overweight → Overweight	—	$14.96	$14.61	-2.3%	-4.0%	-3.4%	-1.4%	+0.1%	+5.4%
Feb 23	Baird	Maintains	Outperform → Outperform	—	$13.83	$16.31	+17.9%	+8.2%	+3.8%	+4.5%	+6.7%	+8.2%
Feb 23	Credit Suisse	Maintains	Outperform → Outperform	—	$13.83	$16.31	+17.9%	+8.2%	+3.8%	+4.5%	+6.7%	+8.2%
Feb 23	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$13.83	$16.31	+17.9%	+8.2%	+3.8%	+4.5%	+6.7%	+8.2%
Jan 17	Goldman Sachs	Maintains	Buy → Buy	—	$13.83	$13.74	-0.7%	-0.4%	+1.4%	+0.9%	+1.6%	+4.9%
Jan 5	UBS	Downgrade	Buy → Neutral	—	$13.98	$13.24	-5.3%	-5.2%	-5.8%	-7.1%	-2.4%	+0.2%
Dec 14	Deutsche Bank	Maintains	Buy → Buy	—	$14.27	$14.58	+2.2%	+6.0%	+5.2%	+3.6%	-0.2%	-0.4%
Dec 7	RBC Capital	Maintains	Outperform → Outperform	—	$12.50	$12.73	+1.8%	+1.7%	+6.4%	+6.2%	+6.4%	+14.2%
Nov 4	Morgan Stanley	Maintains	Overweight → Overweight	—	$14.51	$15.50	+6.8%	+6.9%	-2.4%	-1.8%	-7.2%	+1.4%
Nov 4	Goldman Sachs	Maintains	Buy → Buy	—	$14.51	$15.50	+6.8%	+6.9%	-2.4%	-1.8%	-7.2%	+1.4%
Nov 3	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$15.36	$13.49	-12.2%	-5.5%	+1.0%	-7.8%	-7.2%	-12.3%

Recent Filings

8-K · 5.02 !!! Very High

Unknown — 8-K 5.02: Executive Change

An experienced life sciences executive is joining one of these companies, likely signaling leadership transition or strategic expansion in biotech/pharma sectors, which could impact growth direction and investor confidence.

Apr 7

8-K

Maravai LifeSciences Holdings, Inc. -- 8-K Filing

Maravai LifeSciences announced Q4 2025 results with organizational restructuring and ahead-of-plan cost reductions, signaling management's commitment to operational efficiency and profitability improvement.

Feb 25

Data updated apr 26, 2026 1:19pm · Source: massive.com